Fig. 10: Glutathione depletion by L-Buthionine-sulfoximine (BSO) enhances apoptosis in WT NPCs. | Molecular Psychiatry

Fig. 10: Glutathione depletion by L-Buthionine-sulfoximine (BSO) enhances apoptosis in WT NPCs.

From: Elevated ROS levels during the early development of Angelman syndrome alter the apoptotic capacity of the developing neural precursor cells

Fig. 10

A WT NPCs show a significant reduction in total glutathione levels in response to treatment with 200 µM BSO for 5 h. WT luminescence signal is normalized to MTS absorbance. N  =  3 for each group. B Representative dual-parameter FACS scatter plots of TUNEL assay measuring the percentage of apoptosis in WT-vehicle NPCs and WT-BSO NPCs (20 h treatment with100 µM BSO). C WT-BSO NPCs exhibited a significantly higher percentage of TUNEL+ cells than WT-vehicle NPCs. N = 5 for each group. D Representative dual-parameter FACS scatter plots of Annexin-V versus propidium iodide (PI), measuring the percentage of apoptotic in WT-vehicle and WT-BSO treated NPCs (4 h treatment with 100 µM BSO). E WT-BSO NPCs show an increased percentage of late apoptotic cells and a reduced percentage of viable cells compared to WT-vehicle NPCs, as measured by Annexin-V/PI dual-staining. N  =  4 and N  =  6 for WT-vehicle and WT-BSO NPCs, respectively. Data are presented in means ± SEM (for A and C: **p < 0.01 in t-test, for panel E: ns=non-significant and ****p < 0.0001 in two-way ANOVA).

Back to article page